Cordis Corporation Receives CE Mark For RENLANE™ Renal Denervation System To Treat Resistant Hypertension

FREMONT, Calif.--(BUSINESS WIRE)--Cordis Corporation announced today that it has received European CE Mark for its RENLANE™ Renal Denervation System for the treatment of patients with resistant hypertension and has completed the first successful cases in Europe. The RENLANE™ System consists of a unique, helical shaped, irrigated, multi-electrode ablation catheter with a multi-channel radiofrequency (RF) ablation system.

Help employers find you! Check out all the jobs and post your resume.